An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.

Tacke, Frank et al.·Journal of hepatology·2023·
RPEP-074422023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Published In:
Journal of hepatology, 79(2), 552-566 (2023)
Database ID:
RPEP-07442

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-07442·https://rethinkpeptides.com/research/RPEP-07442

APA

Tacke, Frank; Puengel, Tobias; Loomba, Rohit; Friedman, Scott L. (2023). An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.. Journal of hepatology, 79(2), 552-566. https://doi.org/10.1016/j.jhep.2023.03.038

MLA

Tacke, Frank, et al. "An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.." Journal of hepatology, 2023. https://doi.org/10.1016/j.jhep.2023.03.038

RethinkPeptides

RethinkPeptides Research Database. "An integrated view of anti-inflammatory and antifibrotic tar..." RPEP-07442. Retrieved from https://rethinkpeptides.com/research/tacke-2023-an-integrated-view-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.